Target intelligence / Profile preview

Keratin, type I cytoskeletal 13 (KRT13)

Target
KRT13
Molecular classification
Intermediate filament protein, Structural protein
01

Overview

Keratin, type I cytoskeletal 13 (KRT13), also known as cytokeratin 13, is an acidic type I intermediate filament protein mainly expressed in the suprabasal layers of non-cornified stratified squamous epithelia, particularly in the mucosal linings of the mouth, nose, esophagus, genitals, and anus[1][2][6]. It forms filaments by heterodimerizing with keratin 4, providing mechanical strength and resilience to epithelial tissues against physical stress[1][2][3]. Mutations in KRT13 are causative for white sponge nevus, a benign inherited disorder characterized by thickened white mucosal patches, particularly in the oral cavity[1][6]. Altered expression and function of KRT13 is observed in various epithelial cancers, making it valuable as a diagnostic and prognostic biomarker[4][5][6]. Although KRT13 plays a role in tissue differentiation, homeostasis, and possibly cancer biology, it is not considered a classical therapeutic target such as a receptor, enzyme, or transporter[1][4][5][6].

Other names
Keratin 13Cytokeratin-13CK-13CK13K13Cytokeratin 13MGC3781MGC161462WSN2
02

Biological functions

Provides structural integrity to epithelial cellsMaintains epithelial differentiation and homeostasisCell adhesion and cytoskeleton organization
03

Disease associations

White sponge nevus (autosomal dominant disorder)Cancer (including prostate, oral, cervical, esophageal, bladder, head and neck, breast, lung, colorectal, and gastric cancer; implicated in cancer progression and metastasis)
04

Safety considerations

Disruption may cause fragility of epithelial tissues leading to mucosal lesions and susceptibility to traumaNo known direct drug-related safety concerns
05

Biomarkers

Diagnostic and prognostic biomarker in various carcinomas (prostate, breast, lung, head and neck, oral, and others)Marker of squamous cell differentiation

Beyond the preview

Go deeper on Keratin, type I cytoskeletal 13 (KRT13).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keratin, type I cytoskeletal 13 (KRT13).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call